(11) 98705-3426
TrademarkIQ iconTrademarkIQ
Back to search
Official data from USPTO

MAILI

Did you know this trademark is already registered in United States?

Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.

Active USPTO registrationType: WordOffice: United States

Quick snapshot

MAILI

ST13

US500000079294218

Class

3, 5, 10

Filing

79294218

Registration

6458280

Risk and opportunity diagnosis

Executive reading for naming, filing, and monitoring decisions.

USPTO status

Active USPTO registration

Case type

Application and registration

Recorded events

22

Latest update

02/20/2026

Trademark type

Word

Nice classes

3, 5, 10

Filing date

07/29/2020

Registration date

08/24/2021

Expiration date

-

Complete case details

Structured fields from the responsible authority and the official record.

Status date

08/24/2021

Last transaction

02/20/2026

Responsible office

United States Patent and Trademark Office

Status code

700

Official register

Principal Register

Drawing code

4

Owner type

99

Owner location

GB

Examiner

ENGEL, MICHAEL

Law office

L70

Current location

PUBLICATION AND ISSUE SECTION

Holders and representatives

Holders

Sinclair Pharmaceuticals Limited

Representatives

Gregory Owen Owen, Wickersham & Erickson, P.C.

Technical classification

Nice Classes

Class 3Class 5Class 10

Vienna Codes

No Vienna codes available.

Goods and services

Class 3

Cosmeticsanti-aging cosmetic products and preparationsanti-wrinkle cosmetic products and preparations; anti-wrinkle cosmetic preparationsin the form of injectable preparationsfor the facefor topicalintradermal and subcutaneous application; cosmetic preparationsin the form of injectable preparationsfor skin regeneration; injectable cosmetic preparations; injectable cosmetic preparations for smoothing wrinkles and to provide volumisation of the injected area; injectable cosmetic preparations made from hyaluronic acid

Class 5

Injectable preparations for medical and pharmaceutical purposes for smoothing wrinkles and to provide volumisation of the injected area; injectable dermal fillers; filled syringes for medical purposes for smoothing wrinkles and to provide volumisation of the injected area; pre-filled syringes for medical purposes for smoothing wrinkles and to provide volumisation of the injected area

Class 10

Disposable syringes and needles for medical and surgical use; hypodermic syringes and needles; syringes and needles for injections

Publications

History of USPTO decisions and trademark events.

22 publications found

NREP

NEW REPRESENTATIVE AT IB RECEIVED

02/19/2026

FINO

FINAL DECISION TRANSACTION PROCESSED BY IB

02/27/2022

FICS

FINAL DISPOSITION NOTICE SENT TO IB

02/03/2022

FIMP

FINAL DISPOSITION PROCESSED

02/03/2022

FICR

FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB

11/24/2021

R.PR

REGISTERED-PRINCIPAL REGISTER

08/24/2021

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

06/08/2021

PUBO

PUBLISHED FOR OPPOSITION

06/08/2021

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

05/19/2021

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

05/06/2021

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

05/06/2021

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

05/06/2021

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

05/06/2021

RFNT

REFUSAL PROCESSED BY IB

12/26/2020

RFCS

NON-FINAL ACTION MAILED - REFUSAL SENT TO IB

12/07/2020

RFRR

REFUSAL PROCESSED BY MPU

12/07/2020

RFCR

NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW

11/20/2020

CNRT

NON-FINAL ACTION WRITTEN

11/19/2020

DOCK

ASSIGNED TO EXAMINER

11/17/2020

MAFR

APPLICATION FILING RECEIPT MAILED

10/02/2020

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

09/28/2020

REPR

SN ASSIGNED FOR SECT 66A APPL FROM IB

09/24/2020

Continuous trademark protection

Get notified about every new filing that threatens MAILI or your mark.

Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.